Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions in gynecologic cancer.

D S Alberts1

  • 1Department of Medicine and Arizona Cancer Center, College of Medicine, University of Arizona, Tucson, USA.

Seminars in Oncology
|May 29, 1999
PubMed
Summary

Amifostine protects patients from severe side effects of cisplatin chemotherapy for gynecologic cancers. This cytoprotective agent significantly reduces toxicities, allowing for more effective cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Promising agents for chemoprevention of skin cancer.

Current oncology (Toronto, Ont.)·2012
Same author

Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study.

Cancer causes & control : CCC·2012
Same author

Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.

International journal of immunopathology and pharmacology·2011
Same author

Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Gynecologic oncology·2007
Same author

A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cisplatin is a cornerstone chemotherapy for gynecologic cancers, but its use is limited by significant toxicities like neurotoxicity, ototoxicity, and nephrotoxicity.
  • These dose-limiting toxicities can reduce treatment efficacy and patient quality of life.

Purpose of the Study:

  • To evaluate the role of amifostine as a cytoprotectant against cisplatin-induced toxicities in patients with advanced gynecologic cancers.
  • To explore the potential of amifostine in improving treatment outcomes for ovarian, cervical, and endometrial cancers.

Main Methods:

  • Clinical trials were conducted to assess the impact of concomitant amifostine administration during cisplatin-based chemotherapy.
  • Data on the incidence and severity of dose-limiting toxicities were collected and analyzed.

Main Results:

  • Concomitant administration of amifostine significantly reduced the incidence and severity of cisplatin-induced toxicities.
  • Amifostine demonstrated a protective effect against neurotoxicity, ototoxicity, and nephrotoxicity.

Conclusions:

  • Amifostine is an effective cytoprotectant against cisplatin-induced toxicities in gynecologic cancer patients.
  • Amifostine holds promise for future applications in managing advanced ovarian, cervical, and endometrial cancers, potentially enabling dose intensification and novel combination therapies.

Related Experiment Videos